Thursday, February 7, 2008

NOON – 4:00 pm
Registration

4:00 pm – 4:15 pm
Welcome and Introductions
E. David Crawford, MD

Session I: Prevention

Moderator: Eric A. Klein, MD

4:15 pm – 4:35 pm
Is There a Role for Implementing Prevention Strategies?
Eric A. Klein, MD

4:35 pm – 4:55 pm
Results of the European Consensus on Chemoprevention
Per-Anders Abrahamsson, MD, PhD

4:55 pm – 5:15 pm
Do 5-α-Reductase Agents Induce High-Grade Cancers?
M. Scott Lucia, MD

5:15 pm – 5:35 pm
Is Prostate Cancer an Infectious Disease?
Eric A. Klein, MD

5:35 pm – 5:55 pm
Should Urologists Be More Involved in Men’s Health?
Nelson N. Stone, MD

5:55 pm – 6:15 pm
Question & Answer Session
Moderator: M. Scott Lucia, MD

6:15 pm – 8:30 pm
Posters and Welcome Reception

Friday, February 8, 2008

6:30 am – 7:30 am
Satellite Symposium and Breakfast

Session II: Screening Markers

Moderator: James A. Brown, MD

7:30 am – 7:50 am
Early Detection of Prostate Cancer: What Are the New Diagnostic Tools?
Per-Anders Abrahamsson, MD, PhD

7:50 am – 8:10 am
Promising New Markers
M. Scott Lucia, MD

8:10 am – 8:30 am
The Impact of Tertiary Grade 5 in Men With Gleason Score 7 Prostate Cancer: Implications for Management
Anthony V. D’Amico, MD, PhD

8:30 am – 8:50 am
European Randomized Screening Trial
Per-Anders Abrahamsson, MD, PhD

8:50 am – 9:10 am
Refreshment Break

9:10 am – 9:30 am
Prostate Cancer Prevention Trial
Eric A. Klein, MD

9:30 am – 9:50 am
Testosterone Replacement and Risks of Prostate Cancer
Culley C. Carson III, MD

9:50 am – 10:10 am
Role of ProstaScint/CT Scanning in Staging of Prostate Cancer
James A. Brown, MD

10:10 am – 10:30 am
Question & Answer Session
Moderator: Culley C. Carson III, MD

12:30 pm – 1:30 pm
MEET THE PROFESSORS LUNCHEON

Session III: Localized Disease

Moderator: Anthony V. D’Amico, MD, PhD

3:30 pm – 3:50 pm
Are There Differences in Outcomes Among Surgery Brachytherapy, and External Beam Radiation for Low-Risk and Intermediate-Risk Prostate Cancer?
Eric A. Klein, MD

3:50 pm – 4:10 pm
Radiation and Hormonal Therapy: Current State of the Art and How Drugs Interact
Anthony V. D’Amico, MD, PhD

4:10 pm – 4:30 pm
The New Paradigm for Radiation: Should the Urologist Run the Show?
Nelson N. Stone, MD

4:30 pm – 4:50 pm
Open Versus Laparoscopic Radical Prostatectomy: Is There an Advantage?
James A. Brown, MD

4:50 pm – 5:10 pm
High-Intensity Focused Ultrasonography
Cary N. Robertson, MD

5:10 pm – 5:30 pm
What Should a Radical Prostatectomy Pathology Report Include?
M. Scott Lucia, MD

5:30 pm – 5:50 pm
Looking to the Future: Targeted Focal Therapy
E. David Crawford, MD

5:50 pm – 6:10 pm
Erectile Dysfunction Following Local Treatment
Culley C. Carson III, MD

6:10 pm – 6:30 pm
Question & Answer Session
Moderator: E. David Crawford, MD

6:30 pm – 8:00 pm
Satellite Symposium and Dinner

Saturday, February 9, 2008

6:30 am – 7:30 am
Satellite Symposium and Breakfast

Session IV: Advanced Disease

Moderator: Per-Anders Abrahamsson, MD, PhD

7:30 am – 7:50 am
Multimodal Therapy for Intermediate-Risk and High-Risk Prostate Cancer: The Role of Perioperative Clinical Trials
Cary N. Robertson, MD

7:50 am – 8:10 am
Phoenix, ASTRO, PSA Nadir: How to Define Radiation Failure
Nelson N. Stone, MD

8:10 am – 8:30 am
The COLD Registry for Radiation Salvage
Al Barqawi, MB, FRCS

8:30 am – 8:50 am
Circulating Tumor Cells: What Do They Mean?
Nicholas J. Vogelzang, MD

8:50 am – 9:10 am
Refreshment Break

9:10 am – 9:30 am
Adjuvant Treatment After Radical Prostatectomy
Per-Anders Abrahamsson, MD, PhD

9:30 am – 9:50 am
Current Role of Hormonal Therapy: New Concerns, New Agents
James A. Brown, MD

9:50 am – 10:10 am
Role of Long-Acting LHRH Agonists
Paul D. Maroni, MD

10:10 am – 10:30 am
Question & Answer Session
Moderator: Paul D. Maroni, MD

Session V: Hormone-Refractory Prostate Cancer

Moderator: Nicholas J. Vogelzang, MD

3:30 pm – 4:50 pm
Interactive Case Sessions
Per-Anders Abrahamsson, MD, PhD
Daniel P. Petrylak, MD
Nicholas J. Vogelzang, MD

4:50 pm – 5:10 pm
The Role of the Urologist in HRPC
Per-Anders Abrahamsson, MD, PhD

5:10 pm – 5:30 pm
HRPC: A Look at Phase 2 & 3 Trials Listed on ClinicalTrials.gov
Nicholas J. Vogelzang, MD

5:30 pm – 5:50 pm
New Targets for HRPC
Daniel P. Petrylak, MD

6:00 pm – 7:30 pm
Satellite Symposium and Dinner

Sunday, February 10, 2008

7:30 am – 9:00 am
Highlights and Clinical Pearls

7:30 am– 9:00 am
First International Conference on Targeted Focal Therapy

9:00 am – 10:30 am
Poster Session Presentations

Chairman
E. David Crawford, MD
Professor of Surgery and of Radiation Oncology
Head, Section of Urologic Oncology
University of Colorado Health Sciences Center
Senior Associate Director
University of Colorado Comprehensive Cancer Center
Denver, Colorado

Per-Anders Abrahamsson, MD, PhD
Chairman, Department of Urology
Malmö University Hospital
Professor of Urology
Department of Urology
Lund University
Malmö, Sweden

Al Barqawi, MB, FRCS
Director of Research
Section of Urologic Oncology
University of Colorado at Denver and Health Sciences Center
Assistant Professor
University of Colorado Health Sciences Center
Denver, Colorado

James A. Brown, MD
Associate Professor, Urologic Surgery
Department of Surgery
Section of Urologic Surgery
Medical College of Georgia
Augusta, Georgia

Culley C. Carson III, MD
Rhodes Distinguished Professor of Urology
Chief of Urology
University of North Carolina Hospital
Chapel Hill, North Carolina

Anthony V. D’Amico, MD, PhD
Professor of Radiation Oncology
Harvard Medical School
Chair, Division of Genitourinary Radiation Oncology
Brigham and Women’s Hospital
Boston, Massachusetts

Eric A. Klein, MD
Head, Section of Urologic Oncology
Glickman Urological and Kidney Institute
Cleveland Clinic Foundation
Professor of Surgery
Cleveland Clinic Lerner College of Medicine
Professor of General Medical Sciences
Case School of Medicine
Cleveland, Ohio

M. Scott Lucia, MD
Associate Professor of Pathology
Director, Prostate Diagnostic Laboratory
University of Colorado at Denver and Health Sciences Center
Denver, Coloroado

Paul D. Maroni, MD
Assistant Professor of Urology
Department of Surgery
University of Colorado at Denver and Health Sciences Center
Denver, Colorado

Daniel P. Petrylak, MD
Associate Professor of Medicine
Director, Genitourinary Oncology Program
College of Physicians and Surgeons of Columbia University
New York, New York

Cary N. Robertson, MD
Associate Professor, Surgery and Urology
Department of Surgery
Division of Urology
Duke University Medical Center
Durham, North Carolina

Nelson N. Stone, MD
Clinical Professor of Urology, Oncological Sciences, and Radiation Oncology
Department of Urology
Mount Sinai School of Medicine
New York, New York

Nicholas J. Vogelzang, MD
Director
Nevada Cancer Institute
Professor of Medicine
University of Nevada School of Medicine
Las Vegas, Nevada